OGEN — ORAGENICS INC
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1174940 ·
Last close
$0.21
Market Cap
$947.5K
52W High
$1.11
52W Low
$0.17
ADV30
1,745,743
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 0 | — | -2,255,927 | -2,201,243 | 7,489,636 | 6,107,078 | 1,307,878 |
| Dec 2025 | 0 | — | -2,498,301 | -2,286,870 | 10,067,764 | 4,399,726 | 1,786,359 |
| Sep 2025 | 0 | — | -3,123,773 | -3,066,589 | 12,705,544 | 11,403,766 | 2,874,108 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-9,334,941
Investing CF
$4,000,000
Financing CF
$12,020,941
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-6.14
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-228,829,902
Inventory
—
Receivables
$0
ST Investments
$0
EBIT TTM
$-9,395,742
Pretax Income TTM
$-9,986,272
Interest Exp TTM
$590,530
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -9,362,503 | -9,842,487 | 10,067,764 | 1,786,359 | 8,281,405 | -9,246,387 |
| Dec 2024 | 0 | -10,558,815 | -10,567,918 | 1,472,510 | 1,684,395 | -211,885 | -8,597,382 |
| Dec 2023 | 0 | -20,904,903 | -20,655,737 | 4,966,335 | 1,798,181 | 3,168,154 | -7,290,880 |
| Dec 2022 | 0 | -14,420,768 | -14,288,389 | 14,758,025 | 1,748,723 | 13,009,302 | -15,228,483 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$226,135
NetIncome TTM
$-10,083,409
OpCashFlow TTM
—
Assets (Latest)
$5,492,501
Forward EPS
$-10.80
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SKVI | SKINVISIBLE, INC. | $972.7K | $0.18 | — |
| ATXI | AVENUE THERAPEUTICS, INC. | $922.6K | $0.28 | — |
| APVO | Aptevo Therapeutics Inc. | $834.5K | $0.46 | — |
| GOVX | GeoVax Labs, Inc. | $1.09M | $2.01 | — |
| PTIX | Protagenic Therapeutics, Inc.\new | $814.6K | $0.45 | — |
News headlines (Yahoo Finance, 1h cache)
Oragenics: Q3 Earnings Snapshot
2026-11-12 22:19 · Yahoo
Oragenics Receives NYSE American Approval of Compliance Plan and Extension Through February 2028
2026-11-12 21:00 · Yahoo
Oragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation Forum
2026-09-16 12:30 · Yahoo
Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update
2026-08-28 20:25 · Yahoo
Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling
2026-07-07 12:30 · Yahoo
Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation
2026-05-07 12:30 · Yahoo
Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
2026-04-13 12:30 · Yahoo
Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.
2026-05-05 12:30 · Yahoo
ORAGENICS PROVIDES INVESTOR UPDATE
2026-05-18 12:30 · Yahoo
Sidoti Events, LLC's May Micro-Cap Virtual Conference
2026-05-20 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.